Surgery following neoadjuvant chemotherapy appears to have a number of advantages compared with adjuvant chemotherapy for patients with pancreatic cancer, but there is still some resistance to move to this new strategy, explained Michael A. Choti, MD, MBA. At the 2019 International Society of Gastrointestinal Oncology (ISGIO) Annual Conference, experts discussed the different treatment strategies for patients with pancreatic cancer, 1 of the deadliest forms of cancer discussed at this meeting.
“There are some data to support adjuvant chemotherapy, but what’s really exciting is the newer strategy that I think is becoming more standard to offer prior to surgery: neoadjuvant chemotherapy,” Choti, division chief of surgery at Banner MD Anderson Cancer Center, said during the ISGIO meeting. Read more. . .